ELPA's first NAFLD-NASH meeting gave an introduction to NAFLD – NASH, identifying concrete next steps that would help in tackling this new challenge. With the second edition we focus on prevention and set about exploring approaches to prevent the NAFLD-NASH epidemic in Europe, engaging again with clinicians and policy-makers.
Preventing NAFLD-NASH epidemic in EU– patients' perspective meeting will be hosted by Carlos Moedas, European Commissioner for Science, Research and Innovation, while the confirmed speakers include experts in the field like Prof. Dr. Massimo Colombo, Prof. Dr. Helena Cortez Pinto, Prof. Dr. Quentin M. Antsee, Prof. Dr. Manuel Romero-Gómez and PD Dr. Jörn M. Schattenberg. ELPA will, together with European Patients Forum and their representative Elena Balestra, highlight the importance of patients' engagement in tackling this condition.
European Liver Patients' Association (ELPA) continues to raise awareness on this lifestyle connected condition. NAFLD, which has become the most common chronic liver disorder in Europe and the U.S., and NASH are seen as lifestyle conditions. The socio-economic costs of these conditions are not fully recognized. Current research suggests that being overweight or obese and metabolic syndromes such as type 2 diabetes and hypertension are common conditions in patients affected by NAFLD. The prevalence of NAFLD in the general population ranges from 20% to 30% in Europe and will become the leading cause of liver transplantation in the next 10-20 years. ELPA therefore recognizes this threat to public health and represents efforts of the community in taking the action to establish effective policies for early detection and effective therapies, and put more effort into prevention policies across the European Union.